---
title: "Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: References"
description: "Reference list for the formulary evidence report on Duravyu (vorolanib intravitreal insert, EYP-1901) in Wet age-related macular degeneration. 140 cited documents."
canonical: "https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/references"
published: "2026-09-17T18:16:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: References

<a id="references"></a>

## 5 References

1. [Abbey (2026)](https://www.retinalphysician.com/issues/2026/retina-world-congress/eyp1901-program-overview)
2. [Abbey and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/10/AAO-2025_EYP-1901-DAVIO2-VERONA_25102001.pdf)
3. [Abu Al-Burak et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41812994/)
4. [Al-Khersan et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35636743/)
5. [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)
6. [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)
7. [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11149885/)
8. [Baljoon et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13194801/)
9. [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/)
10. [Brown et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26428606/)
11. [Brown et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32565050/)
12. [Brown et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32681907/)
13. [Brown et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37981235/)
14. [Bryan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12592112/)
15. [Butt et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27637920/)
16. [Chambers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039497/)
17. [Chu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11543832/)
18. [Ciulla et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31324588/)
19. [ClinicalTrials.gov NCT01674569](https://clinicaltrials.gov/study/NCT01674569)
20. [ClinicalTrials.gov NCT01674569 results](https://clinicaltrials.gov/study/NCT01674569?tab=results)
21. [ClinicalTrials.gov NCT02348359](https://clinicaltrials.gov/study/NCT02348359)
22. [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)
23. [ClinicalTrials.gov NCT04747197](https://clinicaltrials.gov/study/NCT04747197)
24. [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)
25. [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)
26. [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)
27. [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)
28. [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)
29. [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/july-2026-medicare-part-b-payment-limit-files.zip)
30. [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/6616fc91-eb70-404c-9f27-1448e47a3a73/DSD_PTB_RY26_P06_V10_DYT24_HCPCS-%20260602.csv)
31. [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)
32. [Congdon et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078664/)
33. [Csaky et al. (2008)](https://doi.org/10.1167/iovs.07-1132)
34. [Dang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11211988/)
35. [Daniel et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3943618/)
36. [Delcourt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13460392/)
37. [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)
38. [Dickson and James (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10492178/)
39. [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf)
40. [Duker (2026)](https://retinalphysician.com/issues/2026/july-august/interpreting-the-lugano-trial/)
41. [Eichenbaum et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39154860/)
42. [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm)
43. [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)
44. [EyePoint Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm)
45. [EyePoint investor conferences and scientific meeting announcement (2026)](https://www.biospace.com/press-releases/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meeting)
46. [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)
47. [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm)
48. [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)
49. [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)
50. [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)
51. [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)
52. [EyePoint Pharmaceuticals DAVIO 2 enrollment completion announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023009850/eypt-ex99_1.htm)
53. [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)
54. [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)
55. [EyePoint Pharmaceuticals DAVIO 2 topline results presentation (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_2.htm)
56. [EyePoint Pharmaceuticals DSMC recommendation announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/d65451dex991.htm)
57. [EyePoint Pharmaceuticals Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025034601/eypt-20241231.htm)
58. [EyePoint Pharmaceuticals Investor Day presentation (2022)](https://www.sec.gov/Archives/edgar/data/1314102/000095017022012766/eypt-ex99_2.htm)
59. [EyePoint Pharmaceuticals investor presentation (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/eypt-ex99_1.htm)
60. [EyePoint Pharmaceuticals LUCIA first patient dosed announcement (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024133076/eypt-ex99_1.htm)
61. [EyePoint Pharmaceuticals LUGANO enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/eypt-ex99_1.htm)
62. [EyePoint Pharmaceuticals LUGANO first patient dosed announcement (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/eypt-ex99_1.htm)
63. [EyePoint Pharmaceuticals phase 3 enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-ex99_1.htm)
64. [EyePoint Pharmaceuticals R&D Day presentation (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024077636/eypt-ex99_1.htm)
65. [EyePoint second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_1.htm)
66. [EyePoint strategic prioritization announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm)
67. [EyePoint third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526456889/eypt-ex99_1.htm)
68. [FDA Non-Inferiority Clinical Trials to Establish Effectiveness guidance (2016)](https://www.fda.gov/media/78504/download)
69. [Flavin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11529448/)
70. [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)
71. [Fonteh et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526530/)
72. [Franco et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42479493/)
73. [Friedman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078675/)
74. [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)
75. [Genentech LUCENTIS prescribing information (2024)](https://www.gene.com/download/pdf/lucentis_prescribing.pdf)
76. [Genentech SUSVIMO prescribing information (2025)](https://www.gene.com/download/pdf/susvimo_prescribing.pdf)
77. [Genentech VABYSMO prescribing information (2026)](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)
78. [Gohil et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4461306/)
79. [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)
80. [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/)
81. [Holz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4316940/)
82. [Holz et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447127/)
83. [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)
84. [Khurana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36858288/)
85. [Klein et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17270675/)
86. [Kuznik et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12534633/)
87. [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)
88. [Leandro et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28829845/)
89. [Liu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11316235/)
90. [Loewenstein et al. (2024)](https://eyepoint.bio/wp-content/uploads/2025/02/EURETINA2024_DAVIO2-1yr_Loewenstein_ePoster_FINAL-091824.pdf)
91. [McGuire et al. (2026)](https://retinatoday.com/articles/2026-may-june/anti-vegf-step-therapy-an-update)
92. [MedPAC (2026)](https://www.medpac.gov/wp-content/uploads/2026/07/July2026_MedPAC_DataBook_Sec10_SEC.pdf)
93. [Monés et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33207259/)
94. [National Eye Institute (2021)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration)
95. [Niazi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31654492/)
96. [NICE (2018)](https://www.nice.org.uk/guidance/ng82/chapter/Recommendations)
97. [Obeid et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583857/)
98. [Ocular Therapeutix first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/0001393434/000110465926055241/tm2613442d1_ex99-1.htm)
99. [Ocular Therapeutix Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm)
100. [Ocular Therapeutix second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm)
101. [Paneerselvam et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41297526/)
102. [Patel (2018)](https://pubmed.ncbi.nlm.nih.gov/31047530/)
103. [Patel and Ribeiro (2025)](https://eyepointpharma.com/wp-content/uploads/2025/05/ARVO-2025_LUGANO-LUCIA_Patel_FINAL.pdf)
104. [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)
105. [Pitsillidou et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42627194/)
106. [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)
107. [Regeneron EYLEA HD prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761355s005lbl.pdf)
108. [Regeneron EYLEA prescribing information (2024)](https://www.regeneron.com/downloads/eylea_fpi.pdf)
109. [Regillo (2024)](https://eyepoint.bio/wp-content/uploads/2025/02/AAOSSD-2024_DAVIO2-1yr_Regillo_Presentation.pdf)
110. [Rein et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)
111. [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)
112. [Rosenfeld et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17021318/)
113. [Rowe et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12360407/)
114. [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)
115. [Sayed et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11497975/)
116. [Schmidt et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42426273/)
117. [Schmidt-Erfurth et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4145443/)
118. [Shah (2026)](https://www.ophthalmologyadvisor.com/reports/single-dose-vorolanib-insert-matches-bimonthly-aflibercept-amd-vision-outcomes/)
119. [Sharma et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10959467/)
120. [Sheth et al. (2024)](https://eyepointpharma.com/wp-content/uploads/2025/02/ASRS-2024_DAVIO2-Wk32-Supplemental-Txt_Sheth_Presentation_24071601.pdf)
121. [Siddiqui et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373014/)
122. [Siktberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10275928/)
123. [Singh and Sørensen (2012)](https://pubmed.ncbi.nlm.nih.gov/21106047/)
124. [Sivaprasad et al. (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_DAVIO-2_Vision-Outcomes_25091001.pdf)
125. [Sood et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9204613/)
126. [Spaide et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559632/)
127. [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)
128. [Van Vu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11156866/)
129. [Varano et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4671808/)
130. [Viola et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39208778/)
131. [Vision Loss Expert Group of the Global Burden of Disease Study (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11269688/)
132. [Vu et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32981226/)
133. [Vukicevic et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4791694/)
134. [Windsor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5732022/)
135. [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)
136. [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)
137. [Wykoff (2024a)](https://eyepoint.bio/wp-content/uploads/2025/02/Angiogenesis-2024_DAVIO-2-Topline-Deck_16Jan2024.pdf)
138. [Wykoff et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11418737/)
139. [Xu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42259444/)
140. [Zhang et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37116720/)

## Related pages
- [Duravyu (vorolanib intravitreal insert): Wet age-related macular degeneration](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Duravyu (vorolanib intravitreal insert): Wet age-related macular degeneration](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/executive-summary.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/clinical-evidence.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/economics.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/prevalence.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/cost-effectiveness-analyses.md)
